Score Overview
Explore the 2021 public Archive ranking →
Where XTL Biopharmaceuticals Ltd ADR has ranked, year by year
Showing 5 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- XTLB
2013: 36.2% · 2021: 20.3% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 2.21 | — |
1 Year2025-09-29 | $ 4.84 | -54.34% |
5 Years2021-09-29 | $ 16.68 | -86.75% |
10 Years2016-09-29 | $ 18.82 | -88.26% |
20 Years2006-09-29 | $ 462.00 | -99.52% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 |
|---|---|---|---|---|---|
| Price | $ 2.21 | $ 4.84 | $ 16.68 | $ 18.82 | $ 462.00 |
| Return | — | -54.34% | -86.75% | -88.26% | -99.52% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 289K | -$ 255K | $ 144K |
| 2025 | $ 0.00 | -$ 6M | $ 144K |
| 2024 | $ 451K | -$ 1M | $ 1M |
| 2023 | $ 0.00 | $ 2M | |
| 2022 | -$ 459K | -$ 1M | $ 3M |
| 2021 | $ 1M | $ 435K | $ 6M |
| 2020 | $ 28K | -$ 782K | $ 6M |
| 2019 | $ 69K | -$ 1M | $ 6M |
| 2018 | $ 52K | $ 2M | $ 8M |
| 2017 | $ 29K | -$ 781K | $ 6M |
| 2016 | $ 23K | -$ 2M | $ 2M |
| 2015 | -$ 6K | -$ 4M | $ 4M |
| 2014 | $ 41K | -$ 2M | $ 2M |
| 2013 | $ 2M | -$ 2M | $ 4M |
| 2012 | $ 938K | -$ 1M | $ 3M |
| 2011 | -$ 1M | $ 1M | |
| 2010 | -$ 1M | $ 1M | |
| 2009 | $ 2M | $ 412K | |
| 2008 | $ 5M | -$ 9M | $ 2M |
| 2007 | $ 907K | -$ 24M | $ 12M |
| 2006 | $ 454K | -$ 15M | $ 25M |
| IPO2005 | $ 3M | -$ 14M | $ 13M |
XTL Biopharmaceuticals Ltd ADR fundamental performance
Between 2015 and 2025, revenue went from -$ 6K to $ 0.00 and net income went from -$ 4M to -$ 6M. Revenue increased in 7 of those 10 years; net income in 6.
Across XTL Biopharmaceuticals Ltd ADR's full reported history, from 2005 to 2025, revenue declined from $ 3M to $ 0.00 and net income went from -$ 14M to -$ 6M. Revenue increased in 65% of the years measured; net income in 47%.
XTL Biopharmaceuticals Ltd ADR currently holds a 20-year HDB Score of 3.1 out of 10. How the HDB Score is calculated.
Membership
Continue XTLB’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
